Company: AEMD
Filing Date: 2025-07-25
Form Type: DRS
Source: 0001683168-25-005397
Chunk: 4

Company: AETHLON MEDICAL INC
Filing Date: 2025-07-25
Form: DRS
Chunk 4
---
 are issuable upon
the exercise of outstanding inducement warrants (the “Inducement Warrants”). We previously issued Inducement Warrants to the
Selling Securityholder in a private placement, pursuant to a Warrant Inducement Agreement dated March 16, 2025.

The Selling
Securityholder may, from time to time, sell, transfer or otherwise dispose of any or all of their common stock or interests in their
common stock on any stock exchange, market or trading facility on which the common stock is traded or in private transactions. These
dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market
price, at varying prices determined at the time of sale, or at negotiated prices. See “Plan of Distribution” in this prospectus for more information. We will not receive any proceeds from the resale or other
disposition of the common stock by the Selling Securityholder. However, we will receive the proceeds of any cash exercise of the
Inducement Warrants. See “Use of Proceeds” beginning on page 25 and “Plan of Distribution” beginning on page 37 of this prospectus for more information. The offering will settle delivery versus
payment (“DVP”)/receipt versus payment (“RVP”). Accordingly, we and the placement agent have not made any
arrangements to place investor funds in an escrow account or trust account since the placement agent will not receive investor funds
in connection with the sale of the securities offered hereunder.

Our common stock is traded
on the Nasdaq Capital Market (“Nasdaq”) under the symbol “AEMD.” On July 24, 2025, the last reported sale price
of our common stock as reported on Nasdaq was $1.35 per share. We are a “smaller reporting company” as defined under the federal
securities laws and, under applicable Securities and Exchange Commission rules, we have elected to comply with certain reduced public
company reporting and disclosure requirements.

You should read this prospectus,
together with additional information described under the headings “Where You Can Find More Information,” carefully before
you invest in any of our securities.

We have agreed to pay the
placement agent fees set forth in the table below, which assumes that we sell all of the securities offered by this prospectus. See “Plan of Distribution” section of this prospectus for more information regarding these arrangements. There is no minimum number of shares
of